Latest Insider Transactions at Travere Therapeutics, Inc. (TVTX)
This section provides a real-time view of insider transactions for Travere Therapeutics, Inc. (TVTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Travere Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Travere Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 05
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,813
-2.89%
|
$149,203
$31.41 P/Share
|
|
Feb 05
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,250
-6.13%
|
$69,750
$31.41 P/Share
|
|
Feb 05
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,250
-5.33%
|
$69,750
$31.41 P/Share
|
|
Feb 05
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,250
-5.38%
|
$69,750
$31.41 P/Share
|
|
Feb 05
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,125
-1.83%
|
$34,875
$31.41 P/Share
|
|
Feb 05
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,125
-2.32%
|
$34,875
$31.41 P/Share
|
|
Feb 04
2021
|
Steve Aselage Director |
BUY
Bona fide gift
|
Indirect |
25,000
+50.0%
|
-
|
|
Feb 04
2021
|
Steve Aselage Director |
SELL
Bona fide gift
|
Direct |
25,000
-13.17%
|
-
|
|
Feb 03
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+9.51%
|
-
|
|
Feb 03
2021
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+10.92%
|
-
|
|
Feb 03
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+9.63%
|
-
|
|
Feb 03
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+6.81%
|
-
|
|
Feb 03
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+9.71%
|
-
|
|
Feb 03
2021
|
Noah L. Rosenberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+8.48%
|
-
|
|
Feb 03
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,406
-1.59%
|
$67,368
$28.91 P/Share
|
|
Feb 03
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,625
-5.17%
|
$101,500
$28.91 P/Share
|
|
Feb 03
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
3,175
-3.94%
|
$88,900
$28.91 P/Share
|
|
Feb 03
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
3,625
-4.51%
|
$101,500
$28.91 P/Share
|
|
Feb 03
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,813
-1.99%
|
$50,764
$28.91 P/Share
|
|
Feb 03
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
563
-0.98%
|
$15,764
$28.91 P/Share
|
|
Feb 02
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
563
-0.97%
|
$16,890
$30.75 P/Share
|
|
Feb 02
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
25,000
-11.28%
|
$750,000
$30.75 P/Share
|
|
Feb 02
2021
|
Steve Aselage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+10.14%
|
$250,000
$10.09 P/Share
|
|
Feb 02
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,625
-4.69%
|
$108,750
$30.75 P/Share
|
|
Feb 02
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
8,734
-2.76%
|
$262,020
$30.18 P/Share
|
|
Feb 02
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
3,175
-3.65%
|
$95,250
$30.75 P/Share
|
|
Feb 02
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
3,625
-4.14%
|
$108,750
$30.75 P/Share
|
|
Feb 02
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,813
-1.92%
|
$54,390
$30.75 P/Share
|
|
Jan 31
2021
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+11.24%
|
-
|
|
Jan 31
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+8.57%
|
-
|
|
Jan 31
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.19%
|
-
|
|
Jan 31
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.08%
|
-
|
|
Jan 31
2021
|
Noah L. Rosenberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+9.48%
|
-
|
|
Jan 21
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
57,260
+28.3%
|
-
|
|
Jan 21
2021
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+30.32%
|
-
|
|
Jan 21
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+20.49%
|
-
|
|
Jan 21
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+27.75%
|
-
|
|
Jan 21
2021
|
Noah L. Rosenberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+25.99%
|
-
|
|
Jan 21
2021
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+27.48%
|
-
|
|
Jan 06
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,438
-3.77%
|
$92,826
$27.01 P/Share
|
|
Jan 06
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
688
-2.78%
|
$18,576
$27.01 P/Share
|
|
Jan 05
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,438
-3.63%
|
$89,388
$26.65 P/Share
|
|
Jan 05
2021
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
688
-2.71%
|
$17,888
$26.65 P/Share
|
|
Dec 15
2020
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
5,549
-2.74%
|
$144,274
$26.02 P/Share
|
|
Dec 02
2020
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
7,891
-3.76%
|
$181,493
$23.43 P/Share
|
|
Nov 25
2020
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,750
-16.15%
|
$82,500
$22.72 P/Share
|
|
Nov 24
2020
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,750
-13.9%
|
$86,250
$23.86 P/Share
|
|
Nov 23
2020
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+21.76%
|
-
|
|
Nov 19
2020
|
Steve Aselage Director |
SELL
Bona fide gift
|
Direct |
3,000
-1.41%
|
-
|
|
Nov 16
2020
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,500
-8.95%
|
$57,500
$23.98 P/Share
|